VICTORIA, BC, April 8,
2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc.
("Eupraxia" or the "Company") (TSX: EPRX); (NASDAQ: EPRX), a
clinical-stage biotechnology company leveraging its proprietary
Diffusphere™ technology to optimize drug delivery for
applications with significant unmet need, announced today that
senior management will deliver a corporate presentation at the 2024
Bloom Burton & Co. Healthcare Investor Conference in
Toronto.
Eupraxia CEO Dr. James
Helliwell will present on April 16th,
2024, at 10:30 am ET at the
Metro Toronto Convention Centre, and will participate in investor
meetings at the conference on April
16th and 17th.
Interested parties can access the presentation through the
following link:
https://wsw.com/webcast/bloomburton9/eprx/2784564
About Eupraxia Pharmaceuticals
Inc.
Eupraxia is a clinical-stage biotechnology company focused on
the development of locally delivered, extended-release products
that have the potential to address therapeutic areas with high
unmet medical need. The Company strives to provide improved patient
benefit and has developed technology designed to deliver targeted,
long-lasting activity with fewer side effects.
Diffusphere™, a proprietary, polymer-based micro-sphere
technology, is designed to facilitate targeted drug delivery, with
extended duration of effect, and offers multiple, highly tuneable
PK profiles. This investigational technology can be engineered for
use with multiple active pharmaceutical ingredients and delivery
methods.
Eupraxia recently completed a Phase 2b clinical trial (SPRINGBOARD) for its lead
product candidate, EP-104IAR, for the treatment of pain due to
osteoarthritis of the knee. The trial met its primary endpoint and
three of the four secondary endpoints. Eupraxia has expanded the
EP-104 platform into gastrointestinal disease with the Phase
1b/2a RESOLVE trial for treating
eosinophilic esophagitis. Eupraxia is also developing a pipeline of
later- and earlier-stage long-acting formulations. Potential
pipeline indications include candidates for other inflammatory
joint indications and oncology, each designed to improve on the
activity and tolerability of currently approved drugs. For further
details about Eupraxia, please visit the Company's website at:
www.eupraxiapharma.com.
Notice Regarding Forward-looking
Statements and Information
This news release includes forward-looking statements and
forward-looking information within the meaning of applicable
securities laws. Often, but not always, forward-looking information
can be identified by the use of words such as "plans", "is
expected", "expects", "scheduled", "intends", "contemplates",
"anticipates", "believes", "proposes", "potential" or variations
(including negative and grammatical variations) of such words and
phrases, or state that certain actions, events or results "may",
"could", "would", "might" or "will" be taken, occur or be achieved.
Forward looking statements in this news release include statements
regarding the Company's product candidates, including expected
benefits to patients; the results gathered from studies and trials
of Eupraxia's product candidates; the potential for the Company's
technology to impact the drug delivery process; and potential
pipeline indications. Such statements and information are based on
the current expectations of Eupraxia's management, and are based on
assumptions, including but not limited to: future research and
development plans for the Company proceeding substantially as
currently envisioned; industry growth trends, including with
respect to projected and actual industry sales; the Company's
ability to obtain positive results from the Company's research and
development activities, including clinical trials; and the
Company's ability to protect patents and proprietary rights.
Although Eupraxia's management believes that the assumptions
underlying these statements and information are reasonable, they
may prove to be incorrect. The forward-looking events and
circumstances discussed in this news release may not occur by
certain dates or at all and could differ materially as a result of
known and unknown risk factors and uncertainties affecting
Eupraxia, including, but not limited to: risks and uncertainties
related to the Company's limited operating history; the Company's
novel technology with uncertain market acceptance; if the Company
breaches any of the agreements under which it licenses rights to
its product candidates or technology from third parties, the
Company could lose license rights that are important to its
business; the Company's current license agreement may not provide
an adequate remedy for its breach by the licensor; the Company's
technology may not be successful for its intended use; the
Company's future technology will require regulatory approval, which
is costly and the Company may not be able to obtain it; the Company
may fail to obtain regulatory approvals or only obtain approvals
for limited uses or indications; the Company's clinical trials may
fail to demonstrate adequately the safety and efficacy of our
product candidates at any stage of clinical development; the
Company may be required to suspend or discontinue clinical trials
due to side effects or other safety risks; the Company completely
relies on third parties to provide supplies and inputs required for
its products and services; the Company relies on external contract
research organizations to provide clinical and non-clinical
research services; the Company may not be able to successfully
execute its business strategy; the Company will require additional
financing, which may not be available; any therapeutics the Company
develops will be subject to extensive, lengthy and uncertain
regulatory requirements, which could adversely affect the Company's
ability to obtain regulatory approval in a timely manner, or at
all; the impact of health pandemics or epidemics on the Company's
operations; the Company's restatement of its consolidated financial
statements, which may lead to additional risks and uncertainties,
including loss of investor confidence and negative impacts on the
Company's common share price; and other risks and uncertainties
described in more detail in Eupraxia's public filings on SEDAR+
(sedarplus.ca) and EDGAR (sec.gov). Although Eupraxia has attempted
to identify important factors that could cause actual actions,
events or results to differ materially from those described in
forward-looking statements and information, there may be other
factors that cause actions, events or results to differ from those
anticipated, estimated or intended. No forward-looking statement or
information can be guaranteed. Except as required by applicable
securities laws, forward-looking statements and information speak
only as of the date on which they are made and Eupraxia undertakes
no obligation to publicly update or revise any forward-looking
statement or information, whether as a result of new information,
future events or otherwise.
View original
content:https://www.prnewswire.com/news-releases/eupraxia-pharmaceuticals-to-present-at-bloom-burton--co-healthcare-investor-conference-302109696.html
SOURCE Eupraxia Pharmaceuticals Inc.